Is it just a CBD deficiency?
I'm not alone in my theory that our disorders and discomforts may be related to a CBD deficiency. Dr. Ethan Russo, believes many disorders, share a lack of what has become known as ‘endocannabinoid tone’ – i.e. how well the ECS performs its core role of keeping balance in the body.
In a recent interview Dr Ethan Russo a pioneering scientist in the endocannabinoid field, describes the ECS as a buffer ‘something that will work both ways as need be. So, for example, in the endocannabinoid system one of its main roles in the brain is to regulate neurotransmitter function and again, if there’s too much of one kind of neurotransmitter it will bring it down, if there’s too little it will bring it up’.
Another example of how the ECS restores balance is with neuropathic pain – a condition associated with MS, HIV and diabetes, but notoriously difficult to treat with pharmaceutical drugs. So the ECS acts as a dimmer switch, upregulating or downregulating when necessary, a principle that can be applied to all systems of the body.
But what happens if the Endocannabinoid System isn’t functioning correctly. According to Dr Russo, ‘If you don’t have enough endocannabinoids you have pain where there shouldn’t be pain. You would be sick, meaning nauseated. You would have a lowered seizure threshold. And just a whole litany of other problems’. Russo sees a pattern between these symptoms and a number of conditions that until now modern medicine has found difficult to treat, namely migraine, irritable bowel syndrome (IBS) and fibromyalgia.
Sceptics might believe this to be pure coincidence, but studies have already shown how the production of the endocannabinoid anandamide might have some bearing on the situation. Russo states ‘available data confirm that the target organs (brain, gut, musculoskeletal system) seem to express lower than normal levels of anandamide, thus providing credence for the concept that they would benefit from treatments that would upregulate the ECS back to normal levels’.
Russo’s named it ‘Clinical Endocannabinoid Deficiency’ (CED) and is based on the concept ‘that many brain disorders are associated with neurotransmitter deﬁciencies, Alzheimer’s disease, parkinsonian syndromes, depression, and that a comparable deﬁciency in endocannabinoid levels might be manifest similarly in certain disorders that display predictable clinical features’ as a result of this deﬁciency.
He believes that supplementing an impaired ECS with plant cannabinoids will bring it back to optimum function, thus provoking an improvement in any many conditions. Here-Here!
Leave a Reply.